Case Studies

Independent Performance Data

Proof-of-concept results demonstrating how the Mirai™ platform delivers established respiratory molecules - benchmarked against reference listed drugs by an independent laboratory.

Respiratory · ICS

Mirai™ DPI Performance Validation

Budesonide Formulation vs. Reference Listed Drug

Independent laboratory testing conducted by Intertek demonstrates that the Mirai™ dry powder inhaler platform achieves near-equivalent aerodynamic particle size distribution (APSD) to established reference listed drugs within 1-2 development iterations.

<5µg
Stages 3-5 Diff
<12µg
Total Profile
1-2
Iterations
Read case study